H.R. 1418 · 118th Congress (2023–2025)
Animal Drug and Animal Generic Drug User Fee Amendments of 2023
This bill reauthorizes the Food and Drug Administration (FDA) to collect fees for brand-name and generic animal drug applications through FY2028. It also makes related updates to fee calculations and FDA reporting requirements.
The bill also (1) provides for a specific fee for requests to establish generic investigational new animal drug files and requires other application fees to be adjusted accordingly; (2) authorizes the FDA to remove species from the definition of major species (currently horses, dogs, cats, cattle, pigs, chickens, and turkeys); and (3) provides statutory authority for the FDA to report on its progress supporting antimicrobial stewardship in veterinary settings (i.e., supporting responsible use of antimicrobial drugs for animals to slow the development of drug-resistant bacteria).
Animal drugs are drugs that are intended for animals other than humans (e.g., pets and livestock). Animal drugs must be approved by the FDA before they may be offered on the commercial market. The FDA is authorized to collect fees for animal drug applications in order to support its regulatory activities; this authority currently expires at the end of FY2023.
Show official title
To amend the Federal Food, Drug, and Cosmetic Act to reauthorize user fee programs relating to new animal drugs and generic new animal drugs.
Expired in Senate
Derived from the legislative history, not an official disposition.
This bill’s path
132 days after it was introduced
This is H.R. 1418’s recorded path, not a universal congressional workflow.
How bills become lawAll actionsIntroduced4 months
Passed House
Passed Senate
Sent to President
Signed into law
Expired
- Sponsor
- Rep. Greg Pence (R-IN-6)
- Cosponsors
2 cosponsors
1 original · 1 later
- Rep. Kim Schrier (D-WA-8)· Original · Mar 7, 2023
- Rep. Susie Lee (D-NV-3)· Later · Jun 6, 2023
- Policy area
- Health
- Subjects
- Research and development
- User charges and fees
- Veterinary medicine and animal diseases
On this page
Timeline
i
In chronological order. Major procedural acts are shown in full. Committee work and ordinary amendments fold in place where they happened, so they do not jump the sequence or stretch the timeline.
Introduced in House
Document: Introduced in House
Sources
- Congress.gov actionIntro-H
- Library of Congress
▸ 7 committee actions · Mar 7, 2023 – Jun 9, 2023
Referred to committee
Referred to the House Committee on Energy and Commerce.
Sources
- Congress.gov action
- House floor actions
Referred to Health
Referred to the Subcommittee on Health.
Sources
- Congress.gov action
- House committee actions
Subcommittee markup session held
Subcommittee Consideration and Mark-up Session Held.
Sources
- Congress.gov action
- House committee actions
Forwarded by subcommittee
Forwarded by Subcommittee to Full Committee in the Nature of a Substitute (Amended) by the Yeas and Nays: 29 - 0 .
Sources
- Congress.gov action
- House committee actions
Markup session held
Committee Consideration and Mark-up Session Held.
Sources
- Congress.gov action
- House committee actions
Ordered reported
Ordered to be Reported (Amended) by the Yeas and Nays: 49 - 0.
Sources
- Congress.gov action
- House committee actions
Reported by committee
Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 118-104.
Sources
- Congress.gov action
- House floor actions
- Latest
Passed House
Congressional Record H3620–H3623
On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote.
The House passed the bill as amended.
Document: Engrossed in House
Sources
- Congress.gov action
- House floor actions
Expired
Passed House → Placed on calendar → No further action before the 118th Congress ended.
Committees
- HouseEnergy and CommerceReferred Mar 7, 2023 · Markup May 24, 2023 · Reported Jun 9, 2023H. Rept. 118-104
May 24, 2023 · Markup
May 17, 2023 · Meeting
Mar 30, 2023 · Hearing
Floor record
i
Explicit consideration evidence: the measure’s bill-status citation matched a GovInfo title, headline, or first paragraph. Incidental mentions are not listed.
Jul 17, 2023 · House · Considered under suspension of the rulesCongressional Record H3620–H3624
Animal Drug and Animal Generic Drug User Fee Amendments of 2023
Text & titles
i
Each distinct name Congress.gov recorded, once. Official, short, display, and popular titles stay distinct when the wording differs. The same wording is not repeated for every text version.
| Version | Date | Links |
|---|---|---|
| Introduced in House | ||
| Reported in House | ||
| Engrossed in House | ||
| Placed on Calendar Senate |
Titles (5)
Animal Drug and Animal Generic Drug User Fee Amendments of 2023
Display title, Short title · Placed on Calendar Senate, Reported in House, Engrossed in House
Animal Generic Drug User Fee Amendments of 2023
Short title · Placed on Calendar Senate, Introduced in House, Reported in House, Engrossed in House · portion of the bill
Animal Drug User Fee Amendments of 2023
Short title · Placed on Calendar Senate, Introduced in House, Reported in House, Engrossed in House · portion of the bill
Animal Drug User Fee Amendments of 2023
Short title · Introduced in House
To amend the Federal Food, Drug, and Cosmetic Act to reauthorize user fee programs relating to new animal drugs and generic new animal drugs.
Official title · Introduced in House